Peter Abel

Dr. Peter Abel serves as a Senior Lecturer at the School of Pharmacy and Biomedical Sciences, University of Central Lancashire. His academic career spans over three decades with a focus on neuro-oncology and cancer immunotherapy research. His work bridges laboratory science with clinical applications in brain tumor treatment.

Education:

• BSc (Hons) in Genetics, Leeds University (1990)
• Masters in Fellowship in Haematology, Manchester Metropolitan University (1993)
• PhD in Characterisation of cytokine secretion in malignant gliomas, University of Central Lancashire (2017)

Dr. Abel's research primarily focuses on glioblastoma and malignant glioma, with particular emphasis on immunotherapeutic approaches including CAR-T cell therapy. His work investigates novel treatment targets, biomarker discovery, and the molecular mechanisms underlying brain tumors. He has developed expertise in both laboratory-based cancer research and translational applications, with publications spanning basic science to clinical perspectives on brain tumor treatment.

Analysis of Dr. Abel's publication history reveals a consistent focus on brain tumor research with evolving methodology. His earlier work centered on diagnostic techniques and biomarker discovery, while more recent publications demonstrate a shift toward immunotherapy applications, particularly CAR-T cell therapy for glioblastoma. The research shows progression from basic characterization of glioma biology toward therapeutic interventions, reflecting the broader field's movement toward targeted and immune-based treatments for these challenging cancers.

Dr. Abel has collaborated extensively with researchers across multiple institutions, particularly evident in his neuro-oncology publications which frequently involve multidisciplinary teams including clinicians, laboratory scientists, and diagnostic specialists. His research demonstrates strong connections between basic science and clinical applications in the challenging field of brain tumor treatment.